Sales and Marketing

Showing 15 posts of 11520 posts found.

celgene_building

NICE recommends Celgene’s Revlimid in treatment-naive multiple myeloma

May 20, 2019 Sales and Marketing Celgene, NICE, Revlimid, UK, multiple myeloma

Celgene’s Revlimid (lenalidomide) has been recommended by NICE for use on the NHS in England and Wales in combination with …
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

May 17, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Gilead, J&J, JJ, Janssen, Mundipharma, Novartis, Teva, generics

Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate …

Pfizer’s Fragmin injection secures FDA approval in paediatric symptomatic venous thromboembolism

May 17, 2019 Medical Communications, Sales and Marketing FDA, Fragmin, Pfizer, pharma

The FDA has announced its approval of Pfizer’s anticoagulant injection Fragmin (dalteparin sodium) for subcutaneous use as a treatment to …

Insider Interview: Paving paths in prostate cancer

May 16, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Interview, Janssen, feature, pharma, prostate cancer

Joaquin Casariego Garcia Luben, Medical Affairs Director Europe, Middle East & Africa, Prostate Cancer for Johnson & Johnson (pictured) discusses …

FDA greenlights Roche and AbbVie’s Venclexta for chronic lymphocytic leukaemia

May 16, 2019 Sales and Marketing AbbVie, Cancer, FDA, Roche, Venclexta, leukaemia, pharma

Venclexta (venetoclax), the oral B-cell lymphoma-2 (BCL-2) inhibitor co-developed by AbbVie and Roche, has been approved by the FDA in …
novartis_window

Novartis’ Kymriah to be covered by Japan’s national insurance system

May 16, 2019 Medical Communications, Sales and Marketing CAR T, CAR-T, Japan, Kymriah, Novartis, pharma

Japan’s national medical insurance system will pay for Novartis’ CAR-T therapy Kymriah following approval from the Central Social Insurance Medical …

EUSA Pharma bolsters senior leadership team with two appointments

May 15, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eusa Pharma, appointment

Rare disease and oncology biopharma firm EUSA Pharma has revealed two new additions to its senior leadership team in two …
123_dott_paolo_chiesi_550

Paola Chiesi awarded honorary doctorate by Karolinska Institutet

May 15, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Paolo Chiesi, Vice President of the Chiesi Group, has been made an Honorary Doctor at the Karolinska Institutet – a …
index_ph001

Two Daiichi Sankyo drugs dealt a thumbs up and thumbs down by FDA advisory panel

May 15, 2019 Research and Development, Sales and Marketing Daiichi Sankyo, FDA, pexidartinib, pharma, quizartinib

Daiichi Sankyo was left with a bittersweet taste in its mouth after it saw one of its drugs recommended for …

Pfizer & Merck’s Inlyta combo becomes first FDA-approved anti-PD-L1 therapy for kidney cancer

May 15, 2019 Research and Development, Sales and Marketing FDA, Merck KGaA, Pfizer, inylta, pharma, renal cell carcinoma

The FDA has approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the treatment of advanced renal cell carcinoma (RCC). …

Ex-GSK, Novartis exec named as Mundipharma’s Head of Access

May 14, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mundipharma, appointment, pharma

Mundipharma has announced that Jerome Moreau has joined the company as its new Head of Market Access. Moreau has amassed …
merck-keytruda

MSD’s Keytruda recommended on NHS in Scotland for Stage 3 melanoma

May 14, 2019 Manufacturing and Production, Sales and Marketing Cancer, MSD, Scotland, Scottish Medicines Consortium, keytruda, melanoma, pharma

MSD has revealed that Keytruda (pembrolizumab) will be made available to NHS Scotland patients after the Scottish Medicines Consortium (SMC) …
shutterstock_87495637

UK GPs are underequipped to handle growing chronic opioid use, report warns

May 13, 2019 Medical Communications, Sales and Marketing NHS, UK, opioid crisis, opioids, pharma

New research from the University of East Anglia (UEA) has argued that general practitioners (GPs) in the UK are lacking …
The Gateway to Local Adoption Series

Latest content